News

A patient living with HIV who received a blood stem cell transplant for high-risk acute myeloid leukemia has been free of the virus for 14 months after stopping HIV antiretroviral drug treatment, suggesting a cure, according to the Weill Cornell Medicine physician-scientists who performed the transplant and managed her care.

Two Weill Cornell Medicine physician-scientists, Dr. Randy Longman and Dr. Robert Schwartz, have been elected as members of the American Society for Clinical Investigation.

Weill Cornell Medicine has been awarded a $9.8 million grant from the National Institutes of Health to lead a consortium of health care institutions that are analyzing nationwide health data in an effort to unravel the complexities of long COVID.

A three-year contract from Wellcome Leap will allow a team of investigators from Weill Cornell Medicine, Stanford Medicine and UC San Diego School of Medicine to study new ways to combat depression and create models that can predict which treatment is likely to work for individual patients.

A specific group of fungi residing in the intestines can protect against intestinal injury and influence social behavior, according to new preclinical research by scientists at Weill Cornell Medicine.

A multi-institutional group in New York City has united to address health disparities in multiple chronic diseases through a new collaborative center.

In his new role, Puccino will financially lead a global health care enterprise embarking on a strategic expansion that will advance the institution’s tripartite mission to care, discover and teach.

An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs.

Scientists at the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine have developed a pipeline that enables genetic manipulation of nonmodel gut bacteria.

Though the COVID-19 pandemic has stymied travel and business-as-usual for many, Cornell’s Office of Academic Integration – which fosters collaborations across disciplines and between the Ithaca and New York City campuses – has thrived.

Awards, honors, prizes and achievements for the month of January.

A growth factor protein produced by rare immune cells in the intestine can protect against the effects of inflammatory bowel disease (IBD), according to a new discovery from Weill Cornell Medicine researchers.

A protein that masterminds the way DNA is wrapped within chromosomes has a major role in the healthy functioning of blood stem cells, which produce all blood cells in the body, according to a new study from researchers at Weill Cornell Medicine.

Using an innovative new imaging technique, researchers at Weill Cornell Medicine have revealed the inner workings of a family of light-sensing molecules in unprecedented detail and speed. 

Paid home care workers are helping patients manage chronic conditions and promoting general and mental health – going well beyond the personal care contributions for which they have been historically associated, according to new Cornell research.

By mapping all the protein interactions of a dementia-linked protein in the brain called Tau, a team of Weill Cornell Medicine investigators has created a road map for identifying potential new treatment targets for Alzheimer’s disease and related dementia.

Dr. Jonathan Power, an assistant professor of psychiatry at Weill Cornell Medicine, has been named a recipient of the second annual 1907 Trailblazer Award from the 1907 Foundation.

Melanoma cells release small extracellular packages containing the protein nerve growth factor receptor, which primes nearby lymph nodes for tumor metastases, according to a new study by Weill Cornell Medicine investigators.

A team led by collaborating researchers from Weill Cornell Medicine, Weill Cornell Medicine—Qatar and Qatar Foundation have assembled a large genomic database on the Qatari people, and have used it to develop an advanced but low-cost screening tool for genetic diseases in this highly distinct Middle Eastern population.

Researchers at Weill Cornell Medicine have developed a pre-clinical model of the leading cause of central vision loss in older individuals, called dry age-related macular degeneration (dry AMD), and used it to identify new treatment modalities and drug targets.